



Universiteit
Leiden
The Netherlands

The fallacy of indexed effective orifice area charts to predict prosthesis-patient mismatch alter prosthesis implantation

Vriesendorp, M.D.; Wijngaarden, R.A.F.D. van; Head, S.J.; Kappetein, A.P.; Hickey, G.L.; Rao, V.; ... ; Klautz, R.J.M.

Citation

Vriesendorp, M. D., Wijngaarden, R. A. F. D. van, Head, S. J., Kappetein, A. P., Hickey, G. L., Rao, V., ... Klautz, R. J. M. (2020). The fallacy of indexed effective orifice area charts to predict prosthesis-patient mismatch alter prosthesis implantation. *European Heart Journal - Cardiovascular Imaging*, 21(10), 1116-1122. doi:10.1093/ehjci/jeaa044

Version: Publisher's Version

License: [Creative Commons CC BY-NC 4.0 license](#)

Downloaded from: <https://hdl.handle.net/1887/3183999>

Note: To cite this publication please use the final published version (if applicable).

The fallacy of indexed effective orifice area charts to predict prosthesis–patient mismatch after prosthesis implantation

Michiel D. Vriesendorp ¹, Rob A.F. De Lind Van Wijngaarden¹, Stuart J. Head², Arie-Pieter Kappetein ², Graeme L. Hickey ², Vivek Rao ³, Neil J. Weissman⁴, Michael J. Reardon⁵, Michael G. Moront⁶, Joseph F. Sabik III⁷, and Robert J.M. Klautz ^{1*}

¹Cardiothoracic Surgery, Leiden University Medical Center, Albinusdreef 2, 2333 ZA Leiden, Netherlands; ²Global Clinical Operations, Coronary and Structural Heart, Medtronic, Endepolsdomein 5, 6229 GW, Maastricht, Netherlands; ³Cardiovascular Surgery, Toronto General Hospital, 200 Elizabeth Street, Toronto, Ontario, Canada; ⁴Cardiovascular Core Laboratories, MedStar Health Research Institute, 6525 Belcrest Road, Suite 700, Hyattsville, MD 20782, USA; ⁵Cardiovascular Surgery, Houston Methodist DeBakey Heart and Vascular Center, 6550 Fannin Street, Houston, TX 77030, USA; ⁶Cardiothoracic Surgery, ProMedica Toledo Hospital, 2109 Hughes Drive, Suite 720, Toledo, OH 43606, USA; and ⁷Cardiac Surgery, University Hospitals Cleveland Medical Center, 11100 Euclid Avenue, Lakeside 7, Cleveland, OH 44106-7060, USA

Received 20 January 2020; editorial decision 25 February 2020; accepted 27 February 2020; online publish-ahead-of-print 3 April 2020

Aims

Indexed effective orifice area (EOAi) charts are used to determine the likelihood of prosthesis–patient mismatch (PPM) after aortic valve replacement (AVR). The aim of this study is to validate whether these EOAi charts, based on echocardiographic normal reference values, can accurately predict PPM.

Methods and results

In the PERIcardial SurGical AOrtic Valve ReplacemeNt (PERIGON) Pivotal Trial, 986 patients with aortic valve stenosis/regurgitation underwent AVR with an AVALUS valve. Patients were randomly split (50:50) into training and test sets. The mean measured EOAs for each valve size from the training set were used to create an AVALUS EOAi chart. This chart was subsequently used to predict PPM in the test set and measures of diagnostic accuracy (sensitivity, specificity, and negative and positive predictive value) were assessed. PPM was defined by an EOAi ≤ 0.85 cm²/m² and severe PPM was defined as EOAi ≤ 0.65 cm²/m². The reference values obtained from the training set ranged from 1.27 cm² for size 19 mm up to 1.81 cm² for size 27 mm. The test set had an incidence of 66% of PPM and 24% of severe PPM. The EOAi chart inaccurately predicted PPM in 30% of patients and severe PPM in 22% of patients. For the prediction of PPM, the sensitivity was 87% and the specificity 37%. For the prediction of severe PPM, the sensitivity was 13% and the specificity 98%.

Conclusion

The use of echocardiographic normal reference values for EOAi charts to predict PPM is unreliable due to the large proportion of misclassifications.

Keywords

prosthesis–patient mismatch • EOAi charts • aortic valve replacement

Introduction

Prosthesis–patient mismatch (PPM) occurs when the effective orifice area (EOA) of a prosthetic heart valve is too small in relation to a

patient's body size, thus resulting in high-residual post-operative pressure gradients across the prosthesis.^{1,2} To classify patients with PPM, a cut-off value of indexed effective orifice area (EOAi), formulated by EOA divided by body surface area (BSA), is used. Although the

* Corresponding author. Tel: +31 (71) 526 9111. E-mail: R.J.M.Klautz@lumc.nl

© The Author(s) 2020. Published by Oxford University Press on behalf of the European Society of Cardiology.

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (<http://creativecommons.org/licenses/by-nc/4.0/>), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com

association between PPM and mortality was not always found in previous studies,^{3,4} the consensus is that PPM negatively affects survival after surgical and transcatheter aortic valve replacement (SAVR and TAVR).⁵⁻⁸ Therefore, prevention of PPM is important for surgeons and cardiologists.

EOAi charts have been developed to aid decisions on choice of specific valve type and size.² These charts represent the projected EOAI for specific patient BSAs, for each valve size and type, based on either *in vitro* or *in vivo* reference EOAs. While tables on these echocardiographic normal reference values of different surgical and transcatheter prosthetic valves are reported across the literature and are reported in clinical guidelines,⁹⁻¹¹ there is little evidence to support the use of these normal reference values in EOAI charts to predict PPM. Therefore, the hypothesis was tested whether projected PPM, derived from EOAI charts, accurately predicts measured PPM.

Methods

Study and patients

The PERIcardial SurGical AOrtic Valve ReplacemeNt (PERIGON) Pivotal Trial is a prospective, non-randomized, international, multicentre trial designed to evaluate the safety and effectiveness of the novel bovine stented AVALUS aortic valve bioprosthesis (ClinicalTrials.gov: NCT02088554). The methods and primary outcomes were previously published.^{12,13} In short, patients with symptomatic moderate or severe aortic stenosis or severe aortic regurgitation were enrolled to undergo SAVR with the AVALUS bioprosthesis (Medtronic, MN, USA). The institutional review board of each centre approved the protocol and written informed consent was obtained from all patients. Selection of the valve size was performed with the use of a sizer probe; the size that corresponded with the largest fitting replica was implanted. Transthoracic echocardiography (TTE) was performed at baseline, discharge, between 3 and 6 months and annually for 5 years. All echocardiographic images were analysed at a single core lab (Cardiovascular Core Laboratories, MedStar Health Research Institute, Hyattsville, MD, USA). For this analysis, only patients who underwent TTE at the first follow-up visit were included, this visit took place between 3 and 6 months after implantation. As only a limited number of patients received a size 17 mm or 29 mm prosthesis, these sizes were excluded from further analysis.

Echocardiographic measurements

Measured EOA was derived with the continuity equation¹⁴; the stroke volume, measured at the level of the left ventricular (LV) outflow tract, was divided by the velocity time integral across the prosthetic valve. Measured EOAI was determined as measured EOA divided by BSA, which was derived according to the Dubois formula at the time of the TTE¹⁴: $BSA (m^2) = \text{weight (kg)}^{0.425} \times \text{height (cm)}^{0.725} \times 0.007184$.¹⁵ PPM was defined by an EOAI $\leq 0.85 \text{ cm}^2/\text{m}^2$; moderate PPM by an EOAI of $0.66\text{--}0.85 \text{ cm}^2/\text{m}^2$, and severe PPM by an EOAI $\leq 0.65 \text{ cm}^2/\text{m}^2$.^{6-8,16}

Training and test sets

For each valve size, patients were randomly split (50:50) into a training set and a test set. To reflect the distribution of valve sizes observed in the PERIGON trial, stratified sampling techniques were used in the data splitting. To assess the variability in measured EOA values in the training dataset, the distribution of measured EOA was plotted for each size. For both groups, the mean measured EOA and the incidence of PPM for each valve

size were determined. In accordance with the current method to determine normal reference EOA values, the mean measured EOA for each valve size from the training dataset was used to construct an EOAI chart. This EOAI chart was subsequently used to calculate the projected EOAI for each patient in the test set, by dividing the reference EOA of the implanted valve size with the BSA of the patient. If this projected EOAI was below $0.85 \text{ cm}^2/\text{m}^2$, the patient was classified as having projected/expected PPM.

Endpoints

The measured EOAI was plotted against the projected EOAI for each patient in the test set. The inaccuracy, sensitivity, specificity, negative predictive value, and positive predictive value of the EOAI chart to predict PPM and severe PPM were calculated.

Statistical analysis

Categorical variables are summarized as number and percentage, and continuous variables are summarized as mean \pm standard deviation. The χ^2 test was used to compare categorical variables between groups, and the independent samples *t*-test was used to compare continuous variables between groups. Sensitivity, specificity, negative predictive value, and positive predictive value of the EOAI chart to predict PPM and severe PPM were expressed in percentages. The correlation between measured and projected EOAI was calculated using Pearson's sample correlation coefficient. To address potential bias in our single split of the data, two-fold Monte Carlo cross-validation was performed. In 1000 iterations, the sensitivity, specificity, negative predictive value, and positive predictive value of the EOAI chart in the prediction of PPM and severe PPM were calculated. The combined results of all iterations were expressed as mean \pm standard deviation.

To exclude low-flow status as an explanation of the misclassifications of PPM, a separate analysis was performed with only the patients with a good LV function [left ventricular ejection fraction (LVEF) $> 50\%$] in the test dataset of the single split. All statistical analyses were performed using R version 3.4.4 (R Development Core Team, Vienna, Austria, 2018).

Results

Of the 1115 patients included in the PERIGON trial, 996 patients underwent a TTE between 3 months and 6 months after implantation. There were no missing data for BSA or EOA for all included patients, but LVEF was missing in 175 (18%) patients. Exclusion of patients with a size 17 mm valve ($n = 1$) and size 29 mm valve ($n = 9$) resulted in a cohort of 986 patients. After randomization, the training and test datasets consisted of 492 and 494 patients, respectively.

Training set

Table 1 displays the patient characteristics stratified by training and test datasets, confirming that the two samples were similar. In the overall training set, 67% of the patients had PPM, and 21% had severe PPM. Size 21 mm had the largest incidence of PPM (77%) and severe PPM (33%). The mean measured EOA ranged from 1.27 cm^2 for size 19 mm up to 1.81 cm^2 for size 27 mm (Table 2). Figure 1 illustrates the distribution of measured EOA values for all valve sizes and stratified for each size. The difference between the minimum and maximum measured EOA was 0.91 cm^2 for size 19 mm, 1.22 cm^2 for size 21 mm, 1.48 cm^2 for size 23 mm, 1.63 cm^2 for size 25 mm, and 1.61

Table 1 Patient characteristics of training vs. test dataset

Patient characteristics	Training dataset (n = 492)	Test dataset (n = 494)	P-value
Baseline			
Age (years)	70 ± 9	70 ± 9	0.79
Male	364 (74%)	378 (77%)	0.40
Body surface area (m ²)	1.99 ± 0.2	1.99 ± 0.2	0.84
BMI (kg/m ²)	29 ± 5	29 ± 5	0.58
STS risk of mortality (%)	1.98 ± 1.4	1.87 ± 1.3	0.17
Diabetes	133 (27%)	126 (26%)	0.64
Hypertension	375 (76%)	367 (74%)	0.53
Peripheral vascular disease	29 (6%)	37 (7%)	0.38
Chronic obstructive lung disease	67 (14%)	49 (10%)	0.09
Left ventricular hypertrophy	204 (41%)	201 (41%)	0.86
Left ventricular ejection fraction (%)	59 ± 9	60 ± 9	0.35
Cardiac output (L/min)	5.2 ± 1.4	5.2 ± 1.4	0.72
Mean aortic gradient (mmHg)	42 ± 18	42 ± 17	0.75
Indexed AVA (cm ² /m ²)	0.45 ± 0.2	0.46 ± 0.3	0.64
Previous aortic valve implanted	5 (1%)	3 (1%)	0.72
Procedure			
Annulus diameter (mm)	23.7 ± 2.1	23.7 ± 2.1	0.79
Isolated AVR	244 (50%)	243 (49%)	0.95
Ascending aorta replacement	32 (7%)	37 (7%)	0.63
Pledget-reinforced sutures	289 (59%)	280 (57%)	0.56
Post-implant mean gradient by TOE (mmHg)	9 ± 5	9 ± 5	0.13

Categorical variables expressed as count (%). Continuous variables expressed as mean ± standard deviation.

AVA, aortic valve area; AVR, aortic valve replacement; BMI, body mass index; STS, Society of Thoracic Surgeons; TOE, transoesophageal echo.

Table 2 EOA and PPM for size 19–27 mm in the training dataset (n = 492)

Valve size	n	Mean measured EOA ± SD (cm ²)	Min EOA (cm ²)	Max EOA (cm ²)	Mean measured EOAI ± SD (cm ² /m ²)	Incidence of true PPM (%)	Incidence of true severe PPM (%)
19	20	1.27 ± 0.3	0.86	1.77	0.76 ± 0.2	70	35
21	90	1.34 ± 0.3	0.82	2.04	0.74 ± 0.2	77	33
23	178	1.51 ± 0.3	0.92	2.40	0.78 ± 0.2	69	23
25	159	1.66 ± 0.3	0.93	2.56	0.81 ± 0.2	63	14
27	45	1.81 ± 0.3	1.08	2.69	0.86 ± 0.2	51	9

EOA, effective orifice area; EOAI, indexed effective orifice area; max, maximum; min, minimum; PPM, prosthesis–patient mismatch.

cm² for size 27 mm (Table 2). The mean measured EOA of each valve size in the training dataset was used to construct a new EOAI chart for the Avalor valve.

Test set

There were some differences between the reference EOAs and the mean measured EOAs in the test set (Table 3). The incidence of PPM and severe PPM was 66% and 24%, respectively. The accuracy of the EOAI chart to predict PPM is illustrated in Figure 2. The sensitivity was 87% to predict PPM, and the specificity was 37%. In addition, the positive predictive value was 73%, and the negative predictive value was 60%. The prediction of PPM was incorrect in 148 (30%) of the patients. In 42 (9%) patients, the projected EOAI was larger than the

measured EOAI, resulting in the incorrect prediction that these patients had no PPM. The opposite occurred in 106 (21%) patients; the projected EOAI was smaller than the measured EOAI, resulting in the incorrect prediction that these patients had PPM. The prediction of PPM and no PPM was correct in 284 (57%) patients and 62 (13%) patients, respectively. The lowest accuracy was reported for the size 27 mm, as the prediction was incorrect in 42% of the patients. The EOAI chart was more accurate for the valve size 19 mm, as PPM was incorrectly predicted for only 5% of the patients (Table 3). In 1000 iterations, the sensitivity to predict PPM was 85 ± 2% and the specificity was 44 ± 4%. The negative predictive value was 60 ± 4%, and the positive predictive value was 75 ± 2%. The prediction of PPM was inaccurate in 29 ± 2% of the patients.




Figure 1 Distribution of measured EOA values for all valve sizes and stratified by size. The red dashed line represents the mean measured EOA. For each valve size, this value would be used as reference EOA in the EOAI chart.

The accuracy of the EOAI chart to predict severe PPM is illustrated in Figure 3. The sensitivity was 13% to predict severe PPM, and the specificity was 98%. In addition, the positive predictive value was 71%, and the negative predictive value was 78%. The prediction of severe PPM was incorrect in 111 (22%) of the patients. In 105 (21%) patients, the projected EOAI was larger than the measured EOAI, resulting in the incorrect prediction that these patients had less than severe PPM. The opposite occurred in 6 (1%) patients; the projected EOAI was smaller than the measured EOAI, resulting in the incorrect prediction that these patients had severe PPM. The prediction of severe PPM and no severe PPM was correct in 15 (3%) patients and 368 (74%) patients, respectively. The lowest accuracy was reported for the size 19 mm as the prediction was incorrect in 45% of the

patients. The EOAI chart was more accurate for the valve size 27 mm as severe PPM was incorrectly predicted for 9% of the patients (Table 3). In 1000 iterations, the prediction of severe PPM had a sensitivity of $14 \pm 3\%$ and a specificity of $98 \pm 1\%$. The negative and positive predictive values were respectively $79 \pm 1\%$ and $65 \pm 9\%$. The prediction of severe PPM was inaccurate in $21 \pm 1\%$ of the patients.

Impact of LV function

Of the 811 patients with reported LVEF, 734 (91%) patients had a good LV function ($LVEF \geq 50\%$). The patients with good LV function were distributed evenly in the training and test sets (50% vs. 50%). The incidence of PPM was 66% and the incidence of severe PPM 23% among patients with good LV function. The Pearson correlation

Table 3 EOA and PPM for size 19–27 mm in the test dataset ($n = 494$)

Valve size	n	Reference EOA (cm^2)	Mean reference EOAI \pm SD (cm^2/m^2)	Mean measured EOA \pm SD (cm^2)	Mean measured EOAI \pm SD (cm^2/m^2)	Incidence of true PPM (%)	Incidence of true severe PPM (%)	Inaccuracy of projected PPM (%)	Inaccuracy of projected severe PPM (%)
19	20	1.27	0.73 ± 0.1	1.16 ± 0.3	0.67 ± 0.2	95	40	5	45
21	91	1.34	0.74 ± 0.1	1.26 ± 0.2	0.70 ± 0.2	84	42	8	34
23	178	1.51	0.77 ± 0.1	1.56 ± 0.3	0.80 ± 0.2	65	22	33	21
25	160	1.66	0.81 ± 0.1	1.66 ± 0.3	0.82 ± 0.2	60	19	34	19
27	45	1.81	0.86 ± 0.1	1.96 ± 0.5	0.93 ± 0.2	42	9	42	9

For each size, the projected EOA in the test set is the mean measured EOA from the training set. EOA, effective orifice area; EOAI, indexed effective orifice area; PPM, prosthesis–patient mismatch.


between projected EOAI and measured EOAI was $r = 0.53$. The sensitivity, specificity, positive predictive value, and negative predictive value for the prediction of PPM were 85%, 56%, 79%, and 66%, respectively. Of the 375 patients, 56 (15%) were misclassified as having PPM and 37 (10%) were misclassified as having no PPM, resulting in a total inaccuracy of 25%. The sensitivity, specificity, positive predictive value, and negative predictive value for the prediction of severe PPM were 11%, 98%, 56%, and 79%, respectively. Nine (2%) patients were misclassified as having severe PPM and 76 (20%) were misclassified as having no severe PPM, resulting in a total inaccuracy of 22%.

Discussion


In this study, the use of an EOAI chart led to the incorrect prediction of PPM in 30% of the patients and severe PPM in 22% of the patients. Because of the weak correlation between the normal reference EOA and the actual measured EOA, projected PPM derived from an EOAI charts does not accurately reflect a prosthetic valve too small for a certain body size. For this reason, studies that analyse the effect of PPM on survival should be based only on individually measured EOA values. Even more important, our findings suggest that EOAI charts should not be used by surgeons and cardiologists to predict PPM.

To select the optimal prosthesis size during SAVR, the conventional method is to use a sizer probe with a barrel that can be passed through the annulus on one end, and a valve replica on the other. This approach should lead to the implantation of a valve with the largest opening that is allowed by the native annulus of the patient. However, this method is considered inappropriate to prevent PPM in all patients, as some patients with a relatively small annulus may need a different type of valve with a larger opening or a larger valve implanted after annular enlargement. To make this clinical judgement, EOAI charts were introduced to predict PPM pre- or peri-operatively.^{2,16} These charts are based on reference EOAs, obtained from either *in vivo* or *in vitro* studies. In this way, for each patient, a projected EOAI can be calculated.

Our study, however, shows that the correlation between these projected EOAI and actually measured EOAI values, was weak ($r = 0.50$), with a sensitivity of 87% and specificity of 37% to predict PPM (Figure 2). This poor specificity calls into question the legitimacy of the use of EOAI charts. Although echocardiographic normal



reference values of surgical and transcatheter prosthetic valves are important to test the overall haemodynamic performance of prostheses, the projected EOAI does not correctly indicate that an annular enlargement or different prosthesis is required. In the current study, 63% of patients with no PPM were classified as projected PPM and were at risk of receiving an unnecessary annular enlargement.¹⁷ The opposite occurred for patients with a false-negative prediction. For these patients, the measured EOAI was underestimated by the projected EOAI, resulting in the incorrect prediction of a lesser degree of PPM, which was observed in 13% of patients with PPM and in 87% of patients with severe PPM. Thus, the EOAI chart would provide a false belief that an adequate prosthesis size is being implanted to prevent (severe) PPM.



Other studies also discussed the accuracy of EOAI charts to predict PPM. While these studies have identified limitations of EOAI charts for the prediction of PPM,^{18,19} none of these studies have used a large single uniform cohort of patients, implanted with a single type of prosthesis and an echocardiogram evaluated by an independent core lab. As part of the error in predicting PPM is likely related to measurement error of EOA in normal reference value charts, the use of a single assessor reduces this error and increases the accuracy of the correlation between projected and measured EOA. Indeed, Bleiziffer *et al.*²⁰ demonstrated that the correlation between projected EOAI and measured EOAI varied strongly between EOAI charts based on institutional data ($r=0.62$), manufacturers data ($r=0.43$), geometric orifice area ($r=0.27$), and literature data ($r=0.53$). Based on these studies, it was suggested to construct EOAI charts with *in vivo* data from the prosthesis' pre-market approval trials, such as the PERIGON Pivotal Trial.²¹ Nevertheless, we demonstrate that despite using *in vivo* data from a single echocardiographic core lab, EOAI charts fail to accurately predict PPM. This finding has important clinical implications, as the current guidelines favour transcatheter aortic valve replacement (TAVR) over SAVR in case of projected/expected PPM. While we do not debate whether transcatheter valves have superior haemodynamic performance compared to surgical valves, the substantial percentage of misclassifications, in the present study, suggest that projected PPM should not be a primary consideration in the decision between SAVR and TAVR.

Our study has furthermore identified that the proportion of misclassifications of PPM and severe PPM varied between valve sizes

(Table 3). For increasing size, the risk of misclassification of PPM also rose; 42% of patients with size 27 mm were incorrectly classified, compared to 5% of patients with size 19 mm. This is due to the fact that the mean measured EOAI of size 27 mm (0.93 cm²/m²) is closer to the cut-off of PPM (≤ 0.85 cm²/m²), compared to the mean EOAI of size 19 mm (0.67 cm²/m²). Thus, a smaller difference between measured and projected EOAI is needed to cause misclassification of PPM for size 27 mm, compared to size 19 mm. The opposite occurs with the prediction of severe PPM, as the mean EOAI of size 19 mm is closer to the cut-off of severe PPM (≤ 0.65 cm²/m²); for size 19 mm, 45% of patients were misclassified as having severe PPM, compared to 9% of patients with size 27 mm. This demonstrates the limited applicability of the use of EOAI charts.

While this study considered measured EOAI as the gold standard, other authors have argued that projected EOAI should be used instead of measured EOAI for the classification of PPM.²² However, the correlation between projected EOAI and post-operative gradient is less than the correlation between measured EOAI and post-operative gradient,²¹ which ultimately forms the theoretical framework to use EOAI as a surrogate for relative valve size.² In addition, when our analysis was limited to patients with good LV function, there was an almost identical rate of false-positive and -negative predictions of PPM and severe PPM. This reduces the likelihood that misclassification was due to insufficient flow to facilitate complete opening of the prosthesis.

The fact that so many patients are misclassified as having PPM, based on reference EOA values, is also relevant for the interpretation of studies that examined the effect of PPM on survival. The majority of studies use reference EOAs derived from the literature to calculate projected EOAI values and determine the presence of PPM.^{6,7} In 30% of the patients in our cohort, the difference between the reference and measured EOA was enough to result in misclassification of PPM. Therefore, the impact on long-term outcomes of PPM based on projected EOA, or the lack of an impact, may be confounded by misclassification bias. This bias is not present when using measured EOA to define PPM. Indeed, two meta-analyses found a higher impact of PPM on perioperative and long-term mortality when measured EOA was used instead of reference *in vivo* EOA.^{6,23} For this reason, we recommend using measured EOA values from each individual patient to study the effect of PPM on clinical outcomes. As a side note,

the use of measured PPM as a surrogate marker for a too small prosthesis is also questionable, however, this is outside the scope of the current study. Future studies should consider whether the relation between EOAI and transprosthetic gradients is sufficient to support the hypothesis that measured PPM reflects a pathologic degree of haemodynamic obstruction. Furthermore, the use of cut-off values to split EOAI, a continuous variable, in different groups of PPM, is debatable.

This study was conducted among patients who underwent SAVR, but the results are also applicable to patients who undergo TAVR. Although no EOAI charts are yet available for the, supposedly, appropriate selection of transcatheter valve and size, normal reference value tables that would allow this have been established.⁹ As these tables with transcatheter valves reported wide distributions of EOA similar to those observed in the current study with surgical valves, we argue against the publication and use of EOAI charts to select the prosthesis size in TAVR.

Limitations

A limitation of this trial is the small number of very large or small valves that were implanted. For this reason, valve sizes 17 mm and 29 mm were excluded from this analysis. Furthermore, the measures of diagnostic accuracy found for the sizes 19 mm and 27 mm have a limited precision. Another limitation of this trial is the missing values of LVEF in 18% of the patients. While this is a substantial proportion, we do not think that these missing data are relevant to the outcomes of the present study, as a similar rate of misclassifications was found in patients with a reported LVEF >50% in comparison to the overall cohort. Moreover, patients with missing LVEF values showed non-significant differences in other haemodynamic parameters at the same visit.

Conclusions

The use of EOAi charts to predict PPM is unreliable, as it inaccurately predicts PPM in 30% of the patients. We recommended the use of measured instead of projected PPM to study the impact of PPM on outcomes.

Funding

The PERIGON Pivotal Trial was funded by Medtronic.

Conflict of interest: M.D.V. reports grants from Medtronic, during the conduct of the study. R.A.F.D.L.V.W. has no conflict of interest to declare. A.-P.K., S.J.H., and G.L.H. are employees of Medtronic. V.R. reports personal fees from Medtronic, during the conduct of the study; personal fees from Abbott Labs, outside the submitted work. N.J.W. reports grants from Medtronic, during the conduct of the study; grants from Abbott Vascular, Boston Scientific, Edwards Lifesciences, LivaNova, and St. Jude, outside the submitted work. M.G.M. reports grants from Medtronic, Edwards, and Abbott, outside the submitted work. M.J.R. reports other from Medtronic (fees for educational services, paid to his department), during the conduct of the study; other from Boston Scientific (fees for educational services, paid to his department), outside the submitted work. J.F.S. reports personal fees from Medtronic; grants from Edwards and Abbott, outside the submitted work. R.J.M.K. reports other from Medtronic, LivaNova, and Edwards, outside the submitted work.

Declaration of Helsinki

The authors state that this study complies with the Declaration of Helsinki, that the locally appointed ethics committees have approved the research protocol and that informed consent has been obtained from the subjects (or their legally authorized representative).

References

1. Rahimtoola SH. The problem of valve prosthesis-patient mismatch. *Circulation* 1978;**58**:20–4.
2. Pibarot P, Dumesnil JG. Hemodynamic and clinical impact of prosthesis–patient mismatch in the aortic valve position and its prevention. *J Am Coll Cardiol* 2000; **36**:1131–41.

3. Jamieson WRE, Ye J, Higgins J, Cheung A, Fradet GJ, Skarsgard P *et al.* Effect of prosthesis-patient mismatch on long-term survival with aortic valve replacement: assessment to 15 years. *Ann Thorac Surg* 2010;**89**:51–9.
4. Swinkels BM, Bas A, Kelder JC, Vermeulen FE, Jurriën M. Prosthesis–patient mismatch after aortic valve replacement: effect on long-term survival. *Ann Thorac Surg* 2016;**101**:1388–94.
5. Rao V, Jamieson WE, Ivanov J, Armstrong S, David TE. Prosthesis-patient mismatch affects survival after aortic valve replacement. *Circulation* 2000;**102**(suppl_3):III5–9.
6. Head SJ, Mokhles MM, Osnabrugge RLJ, Pibarot P, Mack MJ, Takkenberg JJM *et al.* The impact of prosthesis–patient mismatch on long-term survival after aortic valve replacement: a systematic review and meta-analysis of 34 observational studies comprising 27 186 patients with 133 141 patient-years. *Eur Heart J* 2012; **33**:1518–29.
7. Fallon JM, DeSimone JP, Brennan JM, O'Brien S, Thibault DP, DiScipio AW *et al.* The incidence and consequence of prosthesis-patient mismatch after surgical aortic valve replacement. *Ann Thorac Surg* 2018;**106**:14–22.
8. Herrmann HC, Daneshvar SA, Fonarow GC, Stebbins A, Vemulapalli S, Desai ND *et al.* Prosthesis–patient mismatch in patients undergoing transcatheter aortic valve replacement: from the STS/ACC TVT registry. *J Am Coll Cardiol* 2018; **72**:2701–11.
9. Hahn RT, Leipsic J, Douglas PS, Jaber WA, Weissman NJ, Pibarot P *et al.* Comprehensive echocardiographic assessment of normal transcatheter valve function. *JACC Cardiovasc Imaging* 2019;**12**:25–34.
10. Durko AP, Head SJ, Pibarot P, Atluri P, Bapat V, Cameron DE *et al.* Characteristics of surgical prosthetic heart valves and problems around labelling: a document from the European Association for Cardio-Thoracic Surgery (EACTS)—The Society of Thoracic Surgeons (STS)—American Association for Thoracic Surgery (AATS) Valve Labelling Task Force. *Eur J Cardiothorac Surg* 2019;**55**:1025–36.
11. Lancellotti P, Pibarot P, Chambers J, Edvardsen T, Delgado V, Dulgheru R *et al.* Recommendations for the imaging assessment of prosthetic heart valves: a report from the European Association of Cardiovascular Imaging endorsed by the Chinese Society of Echocardiography, the Inter-American Society of Echocardiography, and the Brazilian Department of Cardiovascular Imaging. *Eur Heart J Cardiovasc Imaging* 2016;**17**:589–90.
12. Klautz RJM, Kappetein AP, Lange R, Dagenais F, Labrousse L, Bapat V *et al.*; PERIGON Investigators. Safety, effectiveness and haemodynamic performance of a new stented aortic valve bioprosthesis. *Eur J Cardiothorac Surg* 2017;**52**:425–31.
13. Sabik JF, Rao V, Lange R, Kappetein AP, Dagenais F, Labrousse L *et al.* One-year outcomes associated with a novel stented bovine pericardial aortic bioprosthesis. *J Thorac Cardiovasc Surg* 2018;**156**:1368–77.e5.
14. Richards K. Assessment of aortic and pulmonic stenosis by echocardiography. *Circulation* 1991;**84**(3 Suppl):1182–7.
15. DuBois D. A formula to estimate the approximate surface area if height and body mass be known. *Arch Intern Med* 1916;**17**:863–71.
16. Pibarot P, Dumesnil JG. Prosthesis-patient mismatch: definition, clinical impact, and prevention. *Heart* 2006;**92**:1022–9.
17. Hawkins RB, Beller JP, Mehaffey JH, Charles EJ, Quader MA, Rich JB *et al.* Incremental risk of annular enlargement: a multi-institutional cohort study. *Ann Thorac Surg* 2019;**108**:1752–9.
18. House CM, Nelson WB, Raikar GV, Ahmed I, Dahiya R. How reliable is an effective orifice area indexed chart. *J Heart Valve Dis* 2009;**18**:530–4.
19. Florath I, Albert A, Rosendahl U, Ennker IC, Ennker J. Impact of valve prosthesis-patient mismatch estimated by echocardiographic-determined effective orifice area on long-term outcome after aortic valve replacement. *Am Heart J* 2008;**155**:1135–42.
20. Bleiziffer S, Eichinger WB, Hettich I, Guenzinger R, Ruzicka D, Bauernschmitt R *et al.* Prediction of valve prosthesis–patient mismatch prior to aortic valve replacement: which is the best method? *Heart* 2007;**93**:615–20.
21. Pibarot P, Dumesnil JG, Cartier PC, Méttras J, Lemieux MD. Patient-prosthesis mismatch can be predicted at the time of operation. *Ann Thorac Surg* 2001; **71**(5 Suppl 1):S265–8.
22. Pibarot P, Dumesnil JG. Valve prosthesis–patient mismatch, 1978 to 2011: from original concept to compelling evidence. *Journal of the American College of Cardiology* 2012;**60**:1136–9.
23. Sá MPBO, de Carvalho MMB, Sobral Filho DC, Cavalcanti LRP, Rayol SDC, Diniz RGS *et al.* Surgical aortic valve replacement and patient–prosthesis mismatch: a meta-analysis of 108 182 patients. *Eur J Cardiothorac Surg* 2019;**56**:44–54.